Beijing-based healthcare investment firm Sherpa Healthcare Partners has reached the final close of its oversubscribed maiden U.S. dollar fund to make equity investments in early and growth-stage investments in the fields of biomedicines, medical diagnostic devices, and healthcare services.
Limited partners, or LPs, of the USD-denominated fund included public pension funds, family offices, funds of funds (FOFs), asset management companies, and other institutional investors, Sherpa announced in a WeChat post on July 25.
The dollar fund has already invested in molecular diagnostic startup Singleron Biotechnologies, Shanghai-based biopharmaceutical firm EpimAb Biotherapeutics, Chinese radiology imaging service Nanovision Technology, China-based New Horizon Health, which makes home test kits for colon cancer, and Urotronic, an early-stage medical device firm developing drug/device combination products, according to the post.
Sherpa Healthcare Partners was launched in 2018 and co-led by Cai Daqing. Prior to Sherpa Healthcare Partners, Cai joined Legend Holdings’ venture capital platform Legend Capital in May 2011 and still serves as a managing director, shows the official website of Legend Capital.
Cai led Legend Capital’s investments in companies like Shenzhen-listed clinical genomics and life science company Berry Genomics, drug discovery and development firm Shenogen, medical devices maker BioHermes, and Nasdaq-listed genome analysis firm BioNano.